Abstract: Ca 2+ signalling plays an important role in excitation-contraction coupling and the resultant force output of skeletal muscle. It is also known to play a crucial role in modulating both short-and long-term muscle cellular phenotypic adaptations associated with these events. Ca 2+ signalling via the Ca 2+ /calmodulin (CaM)-dependent phosphatase calcineurin (CnA) and via Ca 2+ /CaM-dependent kinases, such as CaMKI and CaMKII, is known to regulate hypertrophic growth in response to overload, to direct slow versus fast fibre gene expression, and to contribute to mitochondrial biogenesis. The CnA-and CaMK-dependent regulation of the downstream transcription factors nuclear factor of activated T cells (NFAT) and myocyte-specific enhancer factor 2 are known to activate muscle-specific genes associated with a slower, more oxidative fibre phenotype. We have also recently shown the expression of utrophin A, a cytoskeletal protein that accumulates at the neuromuscular junction and plays a role in maturation of the postsynaptic apparatus, to be regulated by CnA-NFAT and Ca 2+ /CaM signalling. This regulation is fibre-type specific and potentiated by interactions with the transcriptional regulators and coactivators GA binding protein (also known as nuclear respiratory factor 2) and peroxisome proliferatoractivated receptor-gamma coactivator 1 alpha. Another downstream target of CnA signalling may be myostatin, a transforming growth factor-b family member that is a negative regulator of muscle growth. While the list of the downstream targets of CnA/NFAT-and Ca 2+ /CaM-dependent signalling is emerging, the precise interaction of these pathways with the Ca 2+ -independent pathways p38 mitogen-activated protein kinase, extracellular signal-regulated kinases 1 and 2, phosphoinositide-3 kinase, and protein kinase B (Akt/PKB) must also be considered when deciphering fibre responses and plasticity to altered contractile load.
Introduction
Skeletal muscle contraction results from voluntary activation of central neural pathways via individual peripheral motor units, the latter characterized as alpha-motoneurons and their constituent muscle fibre targets. Firing of a motoneuron triggers in each of its muscle fibres a depolarization of the postsynaptic membrane, which, in turn, initiates a depolarization wave stemming in a three-dimensional fashion from the motor endplate to adjacent plasma membrane segments, penetrating deep in the muscle fibre via the transverse tubule system. Depolarization of the transverse tubule membrane subsequently leads to activation of the voltagesensing dihydropyridine receptors and signalling across the transverse tubule -sarcoplasmic reticulum gap to the Ca 2+ release channel (ryanodine receptor), triggering release of Ca 2+ from the sarcoplasmic reticulum stores. Once Ca 2+ is released, it binds to troponin C and initiates a cascade of protein-protein interactions that allow actinomyosin binding, cross-bridge cycling, sarcomeric and myofibrillar shortening, and fibre force production. Prolonged or repeated excitation-contraction events translate to similarly prolonged or repeated intracellular Ca 2+ transients, which can ultimately signal changes in muscle cell gene expression. This activation of genes from a series of depolarization-initiated Ca 2+ transients is known as excitation-transcription coupling (Fig. 1) . It is this process that is thought to be the mechanism by which exercise, through either increased skeletal muscle load (i.e., resistance training) or repetitive muscle activation (i.e., aerobic exercise), regulates the establishment of the muscle phenotype characterized, in part, as fibre type proportions, oxidative capacity, contractile strength, and speed.
In this mini-review, Ca 2+ signalling mechanisms that lead to changes in muscle gene expression in response to exercise will be discussed and the mechanisms for regulating 2 specific downstream target genes, utrophin and myostatin, will be highlighted. We will also address whether the deciphering of depolarization-mediated Ca 2+ ,signalling events could lead to therapeutic strategies to counter muscle pathologies and metabolic diseases via altered regulation of utrophin A and myostatin, and the resulting improvements in muscle strength and aerobic capacity.
Decoding the neural signal through CnA/NFAT signalling
Excitation-transcription coupling results in the activation of 2 key downstream Ca 2+ /calmodulin (CaM)-dependent signalling pathways, one modulated by calcineurin (CnA) and the other by Ca 2+ /CaM-dependent kinases (CaMKs) (Fig. 1) . Skeletal muscle fibres can decode information regarding the intensity, duration, and duty cycle of the neural activation envelope at the cellular level via the amplitude and frequency of resulting intracellular Ca 2+ oscillations (see Chin 2005) . Prolonged muscle activation at low depolarization frequencies (8-10 Hz), a pattern typical of slow motor unit firing profiles (Hennig and Lomo 1985) , results in low-amplitude (100-200 nmol/L) but long-duration intracellular Ca 2+ transients. These prolonged low-frequency Ca 2+ transients are shown to activate the CnA-NFAT (nuclear factor of activated T cells) transcriptional signalling pathway (Liu et al. 2001) . This same pathway is not activated during intermittent periods of high frequency (i.e., >50 Hz) depolarizations, leading to brief pulses of high (1-2 mmol/L) intracellular (Ca 2+ ). The latter activation profile is typical of fast motor unit firing patterns (Hennig and Lomo 1985) . In the absence of CnA activation, fibres that are constituents of these motor units are proposed to be free to express genes of a default fast muscle fibre program (Chin et al. 1998) . A recent study using modulatory calcineurin-interacting protein, a muscle-specific endogenous inhibitor of CnA, shows the developmental patterning of slow fibres to be independent of CnA, whereas the maintenance of a slow-fibre phenotype in the adult requires activity of this phosphatase (Oh et al. 2005) . CnA activation regulates the transcription factors NFAT and myocyte-specific enhancer factor 2 (MEF2) and results in activation of downstream target genes that encode slower, more oxidative-type muscle proteins and other genes responsible for muscle growth (Fig. 1) . One of the identified downstream target genes activated in a fibre-type specific manner by prolonged periods of low-frequency neural activation is utrophin A (Chakkalakal et al. 2003) . Another downstream gene target regulated by CnA may be myostatin Muthuri et al. 2007 ), a protein involved in the determination of muscle size (see Fig. 1 and more details later in text).
There is now strong evidence supporting a role for Ca 2+ -dependent transcriptional signalling via CnA-NFAT leading to the beneficial adaptations of skeletal muscle that are associated with exercise (see recent reviews by Bassel-Duby and Olson 2006; Michel et al. 2004 ). The original evidence that CnA-NFAT signalling influences muscle fibre type was based on in vivo studies showing that administration of the CnA inhibitor cyclosporin A (CsA) to rats resulted in an increase in the number of type II (fast) versus type I (slow) fibres (Chin et al. 1998) . These data were supported by in vitro experiments showing selective activation of slow fibre promoters by constitutively active CnA coexpressed with promoter-reporter constructs in C2C12 muscle cells (Chin et al. 1998) . The combined results of in vivo and in vitro data led to the hypothesis that the CnA-NFAT pathway selectively activates a slower, more oxidative, muscle gene program and, upon pharmacological interference of that pathway by CsA, muscle fibres revert to activation of a de-fault, fast, less oxidative genetic program. Subsequent studies further implicated a role for CnA-NFAT signalling in the maintenance of the skeletal muscle phenotype. For example, administration of the CnA inhibitors CsA or FK506 blocks muscle fibre hypertrophy in response to the functional compensatory overload induced by the surgical ablation of synergistic muscles (Dunn et al. 1999 (Dunn et al. , 2000 (Dunn et al. , 2001 (Dunn et al. , 2002 . Moreover, CnA inhibition hinders the recovery of muscle fibre size after unweighting-induced atrophy (Mitchell et al. 2002) . Additionally, administration of these CnA inhibitors induces slow-to-fast phenotype transformations in the normal weightbearing or regenerating slow soleus muscle (Chin et al. 1998; Bigard et al. 2000; Serrano et al. 2001 ). In the overloaded fast plantaris muscle, inhibition of CnA prevents type IIb?IIx?IIa?I myosin heavy chain (MyHC) fibre conversions that lead to an accumulation of slower and more oxidative fibres (i.e., types I and IIa) and, in particular, blocks the typical quadrupling of type I fibres that is characteristic of this model (Dunn et al. 1999) . The thoroughness with which CnA inhibitors prevent these muscle adaptations to overload appears to be largely dosedependent (Fig. 2 , but see Dunn et al. 2002) . Although there remains some controversy in the literature surrounding the role of CnA-NFAT signalling in adaptive growth and muscle regeneration (Dunn et al. 2002; Launay et al. 2006; Parsons et al. 2004; Serrano et al. 2001 ), a considerable amount of evidence supports the importance of CnA signalling via both NFAT and MEF2 in regulating skeletal muscle fibre type and size (for a review, see Michel et al. 2004) .
Although the ability to genetically and pharmacologically manipulate the CnA-NFAT pathway and to detect CnAdependent alterations in muscle phenotype exists, a key remaining question is the importance of this pathway to the exercise-induced adaptations of skeletal muscle. Key data supporting the role of CnA signalling through NFAT and MEF2 in muscle adaptations associated with aerobic exercise and resistance training are provided using transgenic mice harbouring a MEF2-regulated reporter gene (Dunn et al. 2001; Wu et al. 2001) . In these experiments, voluntary wheel running, electrical muscle stimulation, and functional overload are shown to activate muscle fibre MEF2 transcriptional activity. This is achieved via CnA-dependent mechanisms, since reporter expression is inhibited in all these conditions in transgenic mice administered CsA or FK506. NFAT nuclear localisation was also measured under these conditions, and the Cn-dependent shuttling into the nucleus of this transcription factor was found to be similarly induced in working muscle and blocked in ''exercising'' mice treated with Cn inhibitors. These data provide strong evidence that CnA-NFAT and CnA-MEF2 signalling are at the nexus of . Moreover, myostatin itself is recently reported to inhibit CnA signalling (Muthuri et al. 2007) . Abbreviations: Ca, calcium; CaM, calmodulin; CaMKII, calmodulin kinase II; CnA, calcineurin; DHPR, dihydropyridine receptor; ERK, extracellular signal-regulated kinase; GABP, GA binding protein; GSK-3, glycogen synthase kinase 3; HDAC; histone deacetylase; JNK, c-Jun N-terminal kinase; MEF2, myocyte-specific enhancer factor 2; MEKK1, MEK kinase 1; MRFs, myogenic regulatory factors; NFAT, nuclear factor of activated T cells; PGC-1, peroxisome proliferator-activated receptor-gamma coactivator 1; RyR, ryanodine receptor; SERCA, sarco(endo)plasmic reticulum Ca 2+ -ATPase; SR, sarcoplasmic reticulum.
exercise-regulated pathways responsible for muscle fibretype adaptations.
Decoding the neural signal through CaMK signalling
In addition to Ca 2+ -dependent transcriptional signalling through CnA, exercise and exercise training are shown to activate the CaMKII family of enzymes in both animals and humans. In animal models, both aerobic activity (i.e., wheel running) and overload hypertrophy due to stretch can increase Ca 2+ -independent CaMKII activity (Fluck et al. 2000) , suggesting constitutive activation of this pathway. Ca 2+ -independent CaMKII activity is thought to be the mechanism responsible for a postulated muscle ''memory'', where prior bouts of contractile activity determine the type and magnitude of adaptations that a muscle fibre undergoes to adapt to a new load (see Chin 2005) . In humans, acute cycle ergometer exercise also results in Ca 2+ -independent CaMKII activity, and this is shown to be due to increased phosphorylation of CaMKII at Thr 287 , an autophosphorylation event (Rose and Hargreaves 2003) . CaMKII activation results in the downstream phosphorylation of serum response factor and its binding to serum response elements on the promoters of genes such as actin (Fluck et al. 2000) . It is also thought that CaMKII may signal via other as yet unidentified transcription factors to turn on either slower, more oxidative muscle genes or genes involved in muscle growth. Another CaMK pathway implicated in muscle exercise training is CaMKIV. Forced fibre expression of CaMKIV and downstream signalling through peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1a) are shown to be linked to mitochondrial biogenesis (Wu et al. 2002) ; however, controversy remains regarding the specific isoforms of CaMKs that are involved since CaMKIV knockout mice undergo a normal response to aerobic exercise training at the cellular and molecular levels (Akimoto et al. 2004 ). Nonetheless, Ca 2+ signalling through CaMKs are implicated in the activation of both the slower, more oxidative, muscle program of gene expression and the muscle hypertrophic growth program.
Both the increase in strength related to resistance training and the increased oxidative capacity and shift to a more oxidative muscle fibre type (type IIa or type I) observed with endurance training are thought to be important adaptations that underlie the beneficial effects of exercise in countering metabolic disease and age-related frailty, obesity, and diabetes. Given our increased understanding of these exercise-mediated pathways, a question often raised is whether therapeutic interventions via small molecules or biological agents (i.e., DNA, protein, or antibody) could stimulate these pathways and mimic the beneficial effects of exercise. There is now mounting evidence that this is the case, and that activation of Ca 2+ -dependent signalling pathways may provide therapeutic benefits for the treatment of muscle wasting pathologies including muscular dystrophies and metabolic diseases, in particular through activation of the downstream gene targets utrophin A and myostatin. Therefore, an important question with respect to treating muscle diseases and metabolic disorders is whether activation of the Ca 2+ -dependent transcriptional pathways through CnA/NFAT, CaMKII/IV, or both could provide a pharmacological strategy for the treatment of these disorders. The latter part of this review will focus on the evidence supporting this strategy and, in particular, on the role of utrophin A and myostatin as 2 specific downstream target genes that may be key to maintaining a healthy muscle phenotype via activation of these Ca 2+ -dependent pathways.
Utrophin A as a downstream gene target of Ca 2+ signalling
Dystrophin is a cytoskeletal protein that associates at the sarcolemma with a complex of transmembrane proteins collectively referred to as the dystrophin-associated protein complex. This complex plays an important role in maintaining muscle membrane integrity and stability by linking the extracellular matrix to the interior of muscle cells via the actin network (for reviews, see Blake et al. 2002 Plantaris muscles from these mice were sham-operated (sham) or overloaded (OV), and compared after 28 days with respect to (A) fibre cross-sectional area (CSA) and (B) fibre-type proportions. Fibres are grouped according to their expression of the various myosin heavy chain (MyHC) isoforms using specific monoclonal antibodies. Values are means (+SE). Asterisks (p < 0.01) and daggers (p < 0.05) denote significant differences. Note that fibre hypertrophy (A) and overload-related fast-to-slow fibre type (i.e., IIb?IIx?IIa?I MyHC) conversions (B) were only completely blocked with the 25 mg/kg dose administered twice daily. Low CsA dosages (10 mg/kg once daily) did not block fibre hypertrophy, but did partially prevent MyHC conversions of smaller (i.e., IIx/IIa?IIa?I), but not larger (IIb?IIx), fibres.
al. 2005). Lack of dystrophin, as seen in Duchenne muscular dystrophy (DMD) patients and the mdx mouse model, results in increased membrane fragility, leading to fibre damage, repeated cycles of muscle degeneration and regeneration, and muscle weakness. A related protein, utrophin, plays a similar role as dystrophin in its ability to link the extracellular matrix to intracellular structural proteins (Jasmin et al. 2002; Khurana and Davies 2003) . However, utrophin is primarily located in the postsynaptic membrane of the neuromuscular junction, whereas dystrophin is expressed throughout the length of muscle fibres. Owing to mutations and deletions in the dystrophin gene, muscle fibres of DMD patients do not express dystrophin but, importantly, do express its analogous protein, utrophin. Overexpression of utrophin in dystrophin-deficient muscle has therefore become a therapeutic approach of great interest for treating DMD (see Miura and Jasmin 2006) .
Utrophin has 2 isoforms, utrophin A and utrophin B, with the A isoform being primarily expressed in mature skeletal muscle fibres and the B isoform primarily expressed in endothelial cells (Burton et al. 1999; Chakkalakal et al. 2003) . Expression of utrophin A is also shown to be fibretype dependent, with increased levels of utrophin A mRNA and protein in slower, more highly oxidative, muscle fibres (Chakkalakal et al. 2003) . Though largely confined to the neuromuscular junction region of the muscle membrane, utrophin A can also be located extrajuctionally, with MyHC IIb-negative fibres displaying higher extrasynaptic sarcolemmal expression of this protein. Since utrophin A expression is suppressed in animals treated with the CnA inhibitor CsA, and upregulated in transgenic mice that overexpress a constitutively active form of CnA (CnA*), it is concluded that utrophin A expression is CnA-dependent (Chakkalakal et al. 2003) . Moreover, CnA activation results in NFAT dephosphorylation and nuclear translocation, where it can then act in concert with GA binding proteins alpha and beta (also known as nuclear respiratory factor 2), and with PGC-1a on the utrophin A promoter (Angus et al. 2005) . Molecular interactions of these transcription factors and coactivators with the utrophin A promoter cause additive or synergistic activation of utrophin A expression in cultured myocytes (Fig. 1) . These data indicate that regulation of utrophin A in vivo is under the control of multiple signalling pathways, of which CnA-NFAT is an important component.
In vivo studies with transgenic mice overexpressing the activated form of CnA, CnA*, have been used for ''proof of principle'' experiments to determine whether signalling through CnA improves the dystrophic pathology (Fig. 3) . In particular, these experiments were designed to assess whether any improvement in mdx muscle phenotype with activated CnA signalling is related to alterations in utrophin A expression and improved muscle membrane integrity. These experiments were conducted using dystrophindeficient mdx mice as a DMD model (Fig. 3) . Breeding CnA* transgenic mice with mdx counterparts led to offspring (mdx-CnA*) with both genes altered in their skeletal muscle, but displaying a marked rescue of the dystrophic phenotype (Chakkalakal et al. 2004 ). Muscles from transgenic mdx-CnA* mice showed improvements in various markers of muscle damage, including a decrease in central nucleation (indicating denervation or fibre regeneration), a decrease in fibre size variability (indicating fibre degeneration, regeneration, or compensatory hypertrophy), a decrease in the intracellular presence of immunoglobulin M (a marker of sarcolemmal integrity), a decrease in the in vivo muscle fibre uptake of Evan's blue dye (indicating sarcolemmal microdamage), and a decrease in infiltrating immune cells revealed by Mac-1 antibody staining (a marker of an inflammatory response) (see Table 1 ). Muscles from mdx-CnA* mice also showed a shift towards a greater number of oxidative fibres compared with muscles from mdx littermates, and this was correlated with an upregulation of utrophin A expression, particularly within the extrasynaptic sarcolemma of muscle fibres. Thus, attenuation of the muscle pathology associated with dystrophin deficiency is observed when utrophin A is upregulated via activation of CnA-NFAT signalling. Subsequent similar crossbreeding experiments by others (Stupka et al. 2006 ), leading to mdx-CnA* mice with potentiated CnA-NFAT activation, showed related improvements in the contractile function and attenuation of contractile-induced injury in muscles from these animals compared with mdx counterparts, thereby confirming our earlier results (Chakkalakal et al. 2004) .
Since activation of Ca 2+ signalling via CnA can improve the dystrophic phenotype, there was interest in knowing whether inhibition of Ca 2+ -dependent transcriptional pathways would be deleterious to the dystrophic pathology (Fig. 3) . Thus, mdx mice were crossbred with mice expressing a CaM-binding peptide (CaMBP), which inhibits activated Ca 2+ /CaM complexes and, therefore, all downstream signalling of both CnA and CaMKs (Chakkalakal et al. 2006) . Moreover, CaM ''loss of function'' experiments also afforded the possibility to control for the possible confounding features of immune response suppression and aforementioned drug dose-dependency (an issue with systemically delivered CsA). Specifically, mice harbouring the CaMBP transgene, driven by the troponin I slow promoter, had expression limited to a subset of fibres expressing MyHC I, which in the mouse soleus represents *50% of the total fibre complement (the other 50% being type IIa fibres), thus providing an internal muscle control (Fig. 3) . Soleus muscles from mdx/CaMBP crossbred mice showed an exacerbated dystrophic pathology relative to mdx counterparts, and this was associated with a decrease in utrophin A expression (see Table 1 ). The mdx/CaMBP mice showed a shift towards higher type II fibre expression profiles, consistent with this decrease in utrophin A levels. Muscles from these mice also showed an increase in fibre size variability and mononuclear cell infiltration, an increase in collagenous infiltrate, and an increase in Evan's blue staining, all markers of advanced muscle damage. Thus, inhibition of signalling upstream of CnA and CaMK exaggerates the dystrophic pathology. This is consistent with findings that CsA administration to young (18 day old) mdx mice disrupts muscle regeneration and is accompanied by a 30%-35% decrease in maximal force-producing capacity (Stupka et al. 2004) .
In summary, gain-of-function mdx/CnA* crossbreeding experiments support the hypothesis that upregulation of Ca 2+ -dependent pathways, and in particular CnA, can attenu-ate the muscle pathology associated with dystrophin deficiency. This is achieved via upregulation of utrophin A and its role in functionally replacing absent dystrophin, thereby leading to maintenance of muscle membrane integrity. On the other hand, loss-of-function mdx/CaMBP experiments demonstrate that blocking Ca 2+ -dependent signalling pathways can lead to further muscle damage and greater pathology in dystrophin-deficient mice.
Myostatin as a possible downstream gene target of Ca 2+ signalling
A potential downstream gene target implicated in CnAdependent regulation of the muscle phenotype is myostatin (Fig. 1 , but see Michel et al. 2004; Muthuri et al. 2007) . Myostatin, or growth and differentiation factor 8, is a member of the transforming growth factor-beta family of signalling proteins and is a negative regulator of skeletal muscle growth, with its inhibition shown to cause marked increases in muscle size ). Mice harbouring a targeted deletion of the myostatin gene display larger muscle fibres (hypertrophy) and a greater number of these cells (hyperplasia). Belgian blue cattle, with an endogenous mutation in their myostatin gene, are known as double-muscled cattle, in large part owing to muscle hypertrophy (McPherron and Lee 1997).
We recently furthered our earlier findings ) and investigated a plausible role for CnA in the regulation of myostatin, using transgenic approaches that induced either constitutive activation or interference of CnA signalling (Muthuri et al. 2007 ). We found myostatin mRNA levels to be lower in muscles of transgenic mice displaying compromised CnA activity (e.g., CaMBPoverexpressing mice, PV-HA or parvalbumin-overexpressing mice, and NFATc2-/-mice) and higher in transgenic mice with enhanced CnA signalling (e.g., CnA* mice), compared - Fig. 3 . Mouse crossbreeding experiments demonstrate the beneficial effects of calcineurin signalling on the dystrophic phenotype. In vivo proof of concept experiments to support the role of Ca 2+ -dependent transcriptional signalling in ameliorating the muscle degeneration pathology in mdx mice were carried out by crossbreeding the mdx and constitutively active calcineurin (CnA*) transgenic mice (mdxCnA*). These mice were hypothesized to increase utrophin A expression and thus attenuate the dystrophic pathology of mdx mice through upregulation of CnA-NFAT signalling (plus sign). In contrast, crossbreeding the mdx mouse to mice overexpressing a calmodulin inhibitory peptide (CaMBP) was expected to downregulate utrophin A expression and exacerbate the dystrophic pathology because of inhibition of both CnA-NFAT and CAMKII signalling (minus sign). Both hypotheses were supported (Chakkalakal et al. 2004 (Chakkalakal et al. , 2006 . Abbreviations: Ca, calcium; CaM, calmodulin; CaMBP, calmodulin binding protein; CnA, calcineurin; GABP, GA binding protein; MCK, muscle creatine kinase; NFAT, nuclear factor of activated T cells; PGC-1a, peroxisome proliferator-activated receptor-gamma coactivator 1 alpha; TnIs, troponin I slow promoter. with wild-type counterparts. Furthermore, chronic administration of the pharmacological CnA inhibitors CsA or FK506 to control mice resulted in lower muscle myostatin mRNA levels. Interestingly, we also showed myostatin to be involved in a negative regulatory control loop, whereby expression of this protein downregulated CnA expression and signalling via NFATc1 (Muthuri et al. 2007 ). Thus, myostatin appears to be a downstream target gene of the CnA pathway, in a manner associated with muscle growth remodelling, and may itself regulate CnA expression and activity (Fig. 1) .
On the other hand, during acute muscle hypertrophy resulting from ablation of synergistic muscles, plantaris muscles of mice show a decrease in myostatin gene expression, consistent with the increase in muscle size ). This suggests the involvement of competing parallel growth signalling pathways that have an overriding inhibitory regulatory effect on the myostatin gene (Fig. 1) . When CnA and consequently hypertrophic growth are blocked with CsA, so too is this decrease in myostatin mRNA expression , implicating CnA signalling in this inhibitory regulatory cascade that targets specific genes such as myostatin. This would suggest that calcineurin activation triggers both positive regulatory events through NFAT activation, acting ultimately on slow, more highly oxidative genes and the myostatin gene, while also inhibiting expression of the latter and other target genes through some yet to be defined pathways. Such dual regulatory functions would serve to optimize muscle adaptations. Since evidence demonstrating a direct effect of CnA signalling on the myostatin gene is emerging, it is interesting to note that the myostatin gene promoter contains 3 NFAT consensus binding sites, thus lending further credence to these regulatory possibilities. Although there is little evidence linking myostatin gene and protein regulation to exercise adaptations, there is a growing body of literature demonstrating the positive effects of inhibiting myostatin on metabolic diseases (obesity and diabetes) as well as on dystrophic pathologies.
In vivo experiments to address the potential therapeutic benefits of myostatin inhibition in the dystrophic pathology have been completed in mice. Treatment of mdx mice with an anti-myostatin mouse monoclonal antibody results in an increase in muscle mass, an increase in fibre cross-sectional area, a decrease in fibre size variability, decreased cellular infiltration, and increased contractile force (Bogdanovich et al. 2002) . In contrast, administration of recombinant myostatin via CHO cells overexpressing myostatin cDNAs to naïve mice results in muscle cachexia, characterized by decreased muscle mass and muscle fibre size (Zimmers et al. 2002) . It is suggested that myostatin contributes to AIDS-related cachexia, since myostatin expression has been shown to be upregulated in muscles of patients with AIDS (GonzalezCadavid et al. 1998) . Based on the available evidence, myostatin inhibition holds great promise for the treatment of DMD and other muscle-wasting pathologies. It is not, however, known whether improved muscle function is mechanistically related to alterations in utrophin A expression under these conditions.
It is well known that exercise improves glucose disposal, thereby contributing to lowering blood glucose in individuals with type 2 diabetes. It is therefore hypothesized that increasing muscle mass through myostatin inhibition may improve the obese diabetic phenotype by providing an increase in metabolically active tissues favouring glucose disposal. In ''proof of principle'' experiments, mice null for the myostatin gene (Mstn-/-mice) were crossbred with leptindeficient ob//ob mice, which are hyperphagic, have increased fat accumulation, and become insulin resistant and glucose intolerant. Relative to ob//ob mice, ob//ob/Mstn-/-mice had lower fat mass and lower fed glucose levels (McPherron and Lee 2002) . In another study, overexpression of the endogenous inhibitor of myostatin, the myostatin propeptide that binds to and keeps myostatin inactive, was used to examine the response of these mice to a high-fat diet inducing insulin resistance (Zhao et al. 2005) . After 2 months on the high-fat diet, control mice had increased fat mass and became glucose intolerant and insulin resistant. In contrast, the myostatin propeptide mice had increased muscle mass, and maintained normal levels of fat mass, and normal blood glucose and insulin sensitivity. These data suggest that myostatin signalling may contribute to determining dietary fat utilisation and may channel energy gained from fat to adipose tissue. However, when myostatin is inhibited, the muscle may channel energy gained from fat to muscle growth and maintenance. Overall, there is strong evidence to support inhibition of myostatin as being beneficial for both metabolic disease and muscle wasting pathologies. Future studies are required to determine if part of the exercise response includes alterations in myostatin gene expression or changes in myostatin signalling. In addition, further experiments are required to provide a more detailed understanding of the components of the CnA-NFAT signalling pathway that lead to an alteration in myostatin levels.
Summary
In summary, muscle contractile activity can activate Ca 2+ -dependent transcriptional pathways that result in upregulation of key muscle genes that allow the muscle to adapt to both an increased load and an increased demand for oxidative metabolism. This is thought to occur primarily via activation of CnA/NFAT and CaMK II signalling pathways. Two specific downstream target genes of these Ca 2+ -dependent pathways, utrophin A and myostatin, may play important roles in modulating the positive adaptations of skeletal muscle to exercise, and offer novel therapeutic avenues to counter muscle wasting and metabolic disorders. the CIHR. R.N.M. is a Canada Research Chair Tier 1 in Cellular and Molecular Neuromuscular Physiology. J.V.C. is currently at Harvard University (Cambridge, Massachusetts, USA) and J.K.E. is at the Northern Ontario School of Medicine (Sudbury, Ontario, Canada).
